• EdU Imaging Kits for RCC Proliferation Studies

  2026-09-20

  EdU Imaging Kits (HF488) turn S-phase DNA synthesis into a sensitive fluorescence readout for microscopy or flow cytometry. This workflow guide shows how to apply 5-ethynyl-2'-deoxyuridine labeling to renal cancer drug studies, distinguish proliferation effects from cell-death mechanisms, and troubleshoot common assay failures.

• Machine Learning for Senolytic Discovery

  2026-09-19

  The reference study shows that cost-effective machine learning trained only on published screening data can identify senolytic candidates despite small and heterogeneous datasets. Computational screening and human-cell validation identified ginkgetin, periplocin, and oleandrin, demonstrating a potentially lower-cost route to early-stage senolytic discovery.

• Vemurafenib: Reading Resistance in Melanoma Models

  2026-09-18

  Vemurafenib and PLX4032 are powerful tools for dissecting BRAF-mutant melanoma biology. This guide shows how to connect pharmacologic response, temporal signaling, and ARID1A-linked resistance to make melanoma assays more interpretable.

• Latrunculin B: Actin Dynamics Workflow Guide

  2026-09-18

  Use Latrunculin B for controlled, short-duration actin filament assembly inhibition, live-cell morphology studies, and mechanistic controls. Its transient activity also makes it valuable for separating actin-dependent phenotypes from clathrin-mediated processes in carefully timed infection assays.

• Anlotinib hydrochloride in Angiogenesis Assays

  2026-09-17

  Anlotinib hydrochloride connects VEGFR2, PDGFRβ, and FGFR1 inhibition with practical endothelial migration and tube-formation readouts. This workflow shows how to choose concentrations, confirm ERK pathway suppression, benchmark anti-angiogenic activity, and troubleshoot assay variability in cancer research.

• Anlotinib Hydrochloride: From Target to Assay

  2026-09-17

  Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor whose anti-angiogenic activity can be interpreted through a mechanism-resolved assay framework. This guide connects VEGFR2, PDGFRβ, FGFR1, endothelial phenotypes, ERK signaling, and translational pharmacology to improve cancer research design.

• Sodium salicylate NF-κB Inhibitor Workflow

  2026-09-16

  Build reproducible inflammation and oxidative-stress assays with sodium salicylate while distinguishing pathway inhibition from nanomedicine-driven stromal remodeling. This practical guide translates lessons from an acid-responsive pancreatic cancer study into dose-finding, 2D/3D assay, and troubleshooting decisions.

• Ginsenosides and High-Altitude Hypoxia Injury

  2026-09-16

  The 2024 Frontiers in Pharmacology study examines how ginsenosides protect rat lung and kidney tissues during simulated high-altitude hypoxia. Its central contribution is linking improved blood and tissue outcomes to modulation of the PHD2/HIF-1α/EPO pathway, alongside reduced oxidative stress and inflammation.

• Chemerin–cNTS Signaling Raises Sympathetic Activity

  2026-09-15

  The 2024 European Journal of Neuroscience study identifies a chemerin–CMKLR1–NADPH oxidase–superoxide pathway in the caudal nucleus tractus solitarius that increases renal sympathetic nerve activity, arterial pressure, and heart rate. Pharmacological comparison in the paraventricular nucleus further indicates that NMDA, rather than AMPA/kainate, receptor signaling is required for much of this downstream cardiovascular response.

• Ferrostatin-1 in Bladder Cancer Ferroptosis Assays

  2026-09-15

  Ferrostatin-1 (Fer-1) turns ferroptosis experiments into causality tests by rescuing cells from lipid peroxidation rather than merely recording loss of viability. This workflow applies Fer-1 to MCT4, AMPK/ACC, autophagy, and erastin or RSL3 studies in 5637 bladder cancer cells, with practical controls for oxidative lipid damage inhibition.

• VE-821 ATR Kinase Inhibitor Workflow Guide

  2026-09-14

  VE-821 enables selective interrogation of ATR-dependent checkpoint signaling in DNA repair pathway research, radiosensitization assays, and chemotherapy sensitization studies. This practical guide connects reproducible ATR inhibition with the DNMT1-centered findings reported in human bocavirus research, while clearly separating established evidence from cross-domain hypotheses.

• DiI (DiIC18(3)) Plasma Membrane Probe Guide

  2026-09-14

  DiI (DiIC18(3)) is a lipophilic orange fluorescent membrane probe for labeling live or fixed cells and tissues, including workflows involving neuronal tracing, migration, adhesion, fusion, and lipoproteins. It must be prepared in an organic solvent rather than water and should not be treated as an organelle-specific stain.

• Cyclosporin A: Practical Protocols and QC

  2026-09-13

  This guide explains how to prepare, dose, and quality-check Cyclosporin A (cyclosporine) for cell-based studies of cyclophilin activity, calcineurin-NFAT signaling, immune responses, and apoptosis-related endpoints. It is intended for controlled preclinical research and should not be used to infer clinical efficacy, diagnostic performance, or direct antiviral activity.

• Dronedarone (Multaq) Research Workflows

  2026-09-12

  Build reproducible atrial fibrillation and atrial flutter assays with Dronedarone (Multaq), from solvent-controlled dosing to automated whole-cell patch clamp. The workflow uses KCa2 channel profiling and metabolic-interaction experiments to distinguish broad antiarrhythmic pharmacology from direct target activity.

• Optimized hiPSC Platelet Differentiation: Study Insights

  2026-09-11

  Yue and colleagues developed an optimized differentiation scheme that improves megakaryocyte maturation and functional platelet production from human induced pluripotent stem cells. By increasing embryoid body input, refining serum-free media, replacing selected cytokines with small molecules, and promoting polyploidization, the study shortened production time, increased yield, and reduced estimated costs.

8027 records 1/536 page Next 12345 下5页 Last page